Embecta (NASDAQ:EMBC) Sets New 52-Week Low - Here's What Happened

Key Points

• Embecta hit a new 52-week low, trading as low as $9.06 and last at $9.18 on Friday (volume 111,157), well below its 50- and 200-day averages of $11.14 and $12.79 respectively.
• The company slightly beat quarterly EPS ($0.71 vs. $0.67) and revenue expectations and set FY2026 guidance of 2.80–3.00 EPS (analysts’ consensus 2.85), with a low P/E of 3.92 and market cap of about $549.6M.
• Embecta declared a quarterly dividend of $0.15 (a 6.5% yield) while analyst coverage is mixed—average rating "Hold" with a consensus target price of $18.50.

Embecta Corp. (NASDAQ:EMBC - Get Free Report) hit a new 52-week low during trading on Friday . The stock traded as low as $9.06 and last traded at $9.18, with a volume of 111157 shares. The stock had previously closed at $9.44.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Wall Street Zen cut Embecta from a "strong-buy" rating to a "buy" rating in a research report on Saturday, February 7th. BTIG Research reaffirmed a "buy" rating and set a $25.00 target price on shares of Embecta in a report on Friday, February 6th. Finally, Weiss Ratings reissued a "hold (c-)" rating on shares of Embecta in a report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $18.50.

Embecta Stock Down 1.7%

The firm has a market capitalization of $549.56 million, a P/E ratio of 3.92 and a beta of 1.10. The firm's 50-day simple moving average is $11.14 and its 200-day simple moving average is $12.79.

Embecta (NASDAQ:EMBC - Get Free Report) last posted its quarterly earnings data on Thursday, February 5th. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.04. Embecta had a net margin of 12.92% and a negative return on equity of 26.66%. The firm had revenue of $261.20 million for the quarter, compared to analysts' expectations of $258.07 million. During the same quarter last year, the company posted $0.65 EPS. The business's quarterly revenue was down .3% on a year-over-year basis. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. As a group, analysts expect that Embecta Corp. will post 2.85 EPS for the current fiscal year.

Embecta Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 17th. Stockholders of record on Friday, February 27th will be given a dividend of $0.15 per share. The ex-dividend date is Friday, February 27th. This represents a $0.60 annualized dividend and a dividend yield of 6.5%. Embecta's dividend payout ratio is 25.32%.

Institutional Trading of Embecta

Hedge funds and other institutional investors have recently bought and sold shares of the company. Larson Financial Group LLC grew its position in Embecta by 368.6% during the third quarter. Larson Financial Group LLC now owns 2,001 shares of the company's stock valued at $28,000 after acquiring an additional 1,574 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Embecta by 542.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company's stock valued at $71,000 after purchasing an additional 6,224 shares during the last quarter. Wexford Capital LP purchased a new position in Embecta in the 3rd quarter worth $94,000. Humankind Investments LLC bought a new stake in Embecta in the second quarter worth $111,000. Finally, iSAM Funds UK Ltd purchased a new stake in Embecta during the third quarter valued at about $115,000. Hedge funds and other institutional investors own 93.83% of the company's stock.

Embecta Company Profile

Embecta Corp NASDAQ: EMBC is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.